Personalis Q2 revenue rises 30% to $22.4 million on surging clinical test volume - PSNL News | RalliesPersonalis Q2 revenue rises 30% to $22.4 million on surging clinical test volume
P
PSNL• Balance sheet and coverage update
- Cash, cash equivalents and short-term investments totaled about $212.7 million at quarter-end.
- Medicare coverage expanded for NeXT Personal in IO monitoring and neoadjuvant breast cancer.
- Guidance and earnings calls were halted following the Tempus merger agreement.
Q2 revenue and clinical testing growth
- Personalis posted Q2 revenue of $22.4 million, up 30% from $17.2 million.
- Clinical revenue rose 442% to $2.6 million from $0.5 million; clinical test volume jumped 199% to 10,384 tests.
- Pharma testing services and other customer revenue increased 51% to $16.8 million; VA MVP population sequencing revenue fell 9% to $3 million.
